GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

GAMMA Investing LLC raised its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 454.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,539 shares of the company's stock after buying an additional 27,485 shares during the quarter. GAMMA Investing LLC's holdings in Verve Therapeutics were worth $153,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. ProShare Advisors LLC grew its position in shares of Verve Therapeutics by 30.4% in the 4th quarter. ProShare Advisors LLC now owns 24,016 shares of the company's stock worth $135,000 after buying an additional 5,592 shares during the last quarter. Norges Bank bought a new stake in shares of Verve Therapeutics in the 4th quarter worth approximately $441,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Verve Therapeutics by 16.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 144,749 shares of the company's stock worth $816,000 after buying an additional 20,483 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Verve Therapeutics by 25.0% in the 4th quarter. Wells Fargo & Company MN now owns 45,422 shares of the company's stock worth $256,000 after buying an additional 9,083 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics in the 4th quarter worth approximately $50,000. 97.11% of the stock is currently owned by institutional investors.

Verve Therapeutics Stock Up 0.5%

NASDAQ VERV opened at $11.11 on Tuesday. The stock's 50 day moving average is $5.63 and its 200 day moving average is $5.96. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $11.41. The firm has a market capitalization of $990.35 million, a PE ratio of -5.27 and a beta of 1.67.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. On average, research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on VERV shares. William Blair lowered Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a research report on Tuesday, June 17th. Lifesci Capital lowered Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 price target on the stock. in a research report on Wednesday, June 18th. Guggenheim lifted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Jefferies Financial Group lowered Verve Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $11.00 in a research report on Wednesday, June 18th. Finally, Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.75.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.